SCHEMBL3730722

SCHEMBL3730722

CCCOc1ccc(-c2ccccc2[C@@H]2CNCC2C(=O)N2CCOC[C@@H]2c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.71
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 3/20 0.37
TP53 P04637 2/20 0.37
JAK2 O60674 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK1 P28482 1/20 0.35
CYP2D6 P10635 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 2/20 0.34
SCD5 Q86SK9 1/20 0.34
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3730723 1.00 BACE1 (0.71) BACE1SMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL3742009 0.94 BACE1 (0.73) BACE1SMN1; SMN2ALDH1A1TSHRJAK2
SCHEMBL3729012 0.91 BACE1 (0.64) BACE1SMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL3729010 0.91 BACE1 (0.64) BACE1SMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL3730957 0.89 BACE1 (0.59) BACE1SMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL3742380 0.89 BACE1 (0.59) BACE1SMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL3732186 0.88 BACE1 (0.75) BACE1ALDH1A1HPGDTMEM97SIGMAR1
SCHEMBL3736398 0.88 BACE1 (0.75) BACE1ALDH1A1HPGDTMEM97SIGMAR1
SCHEMBL13041213 0.88 BACE1 (0.68) BACE1TMEM97SIGMAR1MAPK1CYP2D6
SCHEMBL3736070 0.87 BACE1 (0.81) BACE1SMN1; SMN2ALDH1A1TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 US disclosed
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 BACE1 1/4885SMN1; SMN2 2112/4885ALDH1A1 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.